A genome-wide survival analysis of 14,406 Alzheimer's disease (AD) cases and 25,849 controls identified eight previously reported AD risk loci and 14 novel loci associated with age at onset. Linkage disequilibrium score regression of 220 cell types implicated the regulation of myeloid gene expression in AD risk. The minor allele of rs1057233 (G), within the previously reported CELF1 AD risk locus, showed association with delayed AD onset and lower expression of SPI1 in monocytes and macrophages. SPI1 encodes PU.1, a transcription factor critical for myeloid cell development and function. AD heritability was enriched within the PU.1 cistrome, implicating a myeloid PU.1 target gene network in AD. Finally, experimentally altered PU.1 levels affected the expression of mouse orthologs of many AD risk genes and the phagocytic activity of mouse microglial cells. Our results suggest that lower SPI1 expression reduces AD risk by regulating myeloid gene expression and cell function.
We thank the patients, control subjects and their family members for participating in and supporting the research projects included in this study. We thank M. Diamond (UT Southwestern Medical Center) for the BV2 cell line and the Flow Cytometry CORE at the Icahn School of Medicine at Mount Sinai Hospital.
IGAP: This study incorporated imputed summary results from the GERAD1 genome-wide association study. GERAD was supported by the Wellcome Trust, the MRC, Alzheimer's Research UK (ARUK) and the Welsh government. ADGC and CHARGE were supported by the US National Institutes of Health, National Institute on Aging (NIH-NIA), including grants U01 AG032984 and R01 AG033193. CHARGE was also supported by Erasmus Medical Center and Erasmus University.
Cardiff University was supported by the Wellcome Trust, Medical Research Council (MRC), Alzheimer's Research UK (ARUK) and the Welsh Assembly Government. Cambridge University and Kings College London acknowledge support from the MRC. ARUK supported sample collections at the South West Dementia Bank and the Universities of Nottingham, Manchester and Belfast. The Belfast group acknowledges support from the Alzheimer′s Society, Ulster Garden Villages, N. Ireland R&D Office and the Royal College of Physicians/Dunhill Medical Trust. The MRC and Mercer's Institute for Research on Aging supported the Trinity College group. The South West Dementia Brain Bank acknowledges support from Bristol Research into Alzheimer's and Care of the Elderly. The Charles Wolfson Charitable Trust supported the OPTIMA group. Washington University was funded by NIH grants, Barnes Jewish Foundation and by the Charles and Joanne Knight Alzheimer's Research Initiative. Patient recruitment for the MRC Prion Unit/UCL Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Biomedical Centre and NIHR Queen Square Dementia Biomedical Research Unit. LASER-AD was funded by Lundbeck SA. The Bonn group was supported by the German Federal Ministry of Education and Research (BMBF), Competence Network Dementia and Competence Network Degenerative Dementia and by the Alfried Krupp von Bohlen und Halbach-Stiftung. The GERAD Consortium also used samples ascertained by the NIMH AD Genetics Initiative.
The KORA F4 studies were financed by Helmholtz Zentrum München; German Research Center for Environmental Health; BMBF; German National Genome Research Network and the Munich Center of Health Sciences. The Heinz Nixdorf Recall cohort was funded by the Heinz Nixdorf Foundation (Dr. jur. G.Schmidt, Chairman) and BMBF. Coriell Cell Repositories is supported by NINDS and the Intramural Research Program of the National Institute on Aging. We acknowledge use of genotype data from the 1958 Birth Cohort collection, funded by the MRC and the Wellcome Trust, which was genotyped by the Wellcome Trust Case Control Consortium and the Type-1 Diabetes Genetics Consortium, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, National Human Genome Research Institute, National Institute of Child Health and Human Development and Juvenile Diabetes Research Foundation International.
ADNI: Data collection and sharing for this project was funded by the Alzheimer′s Disease Neuroimaging Initiative (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company, Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (https://fnih.org/). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
We thank the Cardiogenics (European Project reference LSHM-CT-2006-037593) project for providing summary statistics for the cis-eQTL-based analyses. We also thank the ENCODE Consortium and R. Myers' lab (HAIB) for providing ChIP-seq datasets.
This work was supported by grants from the National Institutes of Health (U01 AG049508, R01-AG035083 and RF-AG054011 (to A.M.G.) and R01-AG044546 and RF1AG053303 (to C.C.)), the JPB Foundation (to A.M.G.) and F Prime (to A.M.G.). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991 and P01 AG026276. Kuan-lin Huang received fellowship funding in part from the Ministry of Education in Taiwan and the Lucille P. Markey Special Emphasis Pathway in Human Pathobiology. Ke Hao is partially supported by the National Natural Science Foundation of China (Grant Nos. 21477087 and 91643201) and by the Ministry of Science and Technology of China (Grant No. 2016YFC0206507). This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders and the Departments of Neurology and Psychiatry at Washington University School of Medicine.
Integrated supplementary information
Quality control of the age-at-onset survival GWAS. The number of filtered SNPs and samples are shown for each of the 7 cohort included for the IGAP meta-analysis. Additionally, the Schoenfeld P values were recorded for each of the 22 top AAOS GWAS SNPs across the 7 IGAP cohorts, and the covariates in Cox models for the ADGC and GERAD cohorts.
Association results from the previous IGAP logistic regression and the matching cohort logistic regression of the 22 top AD-associated SNPs in AAOS GWAS.
The 22 top SNPs significantly associated with age-at-onset defined survival in AD and their tag SNPs (R2 ≥ 0.8).
Significant cis-eQTL associations between the 22 survival-associated SNPs across 10 brain regions in the BRAINEAC dataset.Bonferroni-corrected threshold: P=0.05/292,000 probes = 1.7x10-7.
Significant cis-eQTL associations between the 22 survival-associated SNPs across tissues in the GTEx dataset.
LD score regression analysis results for IGAP AD and PGC SCZ GWAS SNP heritability partitioned using 220 human cell types (CT, and 10 cell type groups, CTG)-specific functional annotations as described by Finucane et al.
Replication of monocyte/macrophage cis-eQTL associations in CD14+ human monocytes from 432 individuals of European ancestry.Bonferroni-corrected threshold: P=0.05/15421 probes = 3.24x10-6.
Coloc analysis results for the SPI1/CELF1, MS4A and SELL loci, using AAOS GWAS SNPs and Cardiogenics monocyte (MC) or macrophage (MP) cis-eQTL datasets.Estimated posterior probabilities for the following mutually exclusive hypotheses are shown in bold when surpassing the threshold PP ≥ 0.8: H0, neither trait has a genetic association in the region; H1: only trait 1 (cis-eQTL) has a genetic association in the region; H2: only trait 2 (GWAS) has a genetic association in the region; H3: both traits are associated, but with different causal variants; H4: both traits are associated and share a single causal variant.
Conditional analysis of monocyte/macrophage SPI1 eQTL associations of 6 SNPs of interest: rs1057233, rs10838698, rs10838699, rs7928163, rs1377416, and rs10838725.Bonferroni-corrected threshold: P=0.05/6 SNPs = 0.00833.
SMR/HEIDI analysis results for 6 SNPs of interest in the SPI1/CELF1 locus: rs1057233, rs10838698, rs10838699, rs7928163, rs1377416 and rs10838725, using AAOS GWAS SNPs and Cardiogenics monocyte (MC) or macrophage (MP) cis-eQTL datasets.Bonferroni-corrected threshold: SMR P=0.05/(6 SNPs x 17 probes) = 0.00049 [green cells]. A nominal significance threshold P ≥ 0.05 [red cells] is used for the HEIDI test as motivated by Zhu et al. Only probes with nominally significant SMR P are shown.
AD-associated genes expressed in human brain myeloid cells with nearby SPI1 (PU.1) binding sites in human blood myeloid cells.
LD score regression analysis results for IGAP AD and PGC SCZ GWAS SNP heritability partitioned using SPI1 (PU.1) ChIP-Seq binding sites in human monocytes and macrophages, as well as SPI1 (PU.1) and POLR2AphosphoS5 ChIP-Seq binding sites in human HL60 cells.
Genes regulated in BV2 microglial cells with differential expression of Spi1.
Primers used for qPCR validation of gene expression in BV2 microglial cells.